| Literature DB >> 34716429 |
Kateryna Shostak1,2, Alain Chariot3,4,5, Seng Chuan Tang1,2, Quentin Lion1,2, Olivier Peulen1,6, Philippe Chariot1,2, Arnaud Lavergne1,7, Alice Mayer1,7, Paula Allepuz Fuster1,2, Pierre Close1,8,9, Sebastian Klein10, Alexandra Florin10, Reinhard Büttner10, Ivan Nemazanyy11.
Abstract
ERα signaling drives proliferation, survival and cancer initiation in the mammary gland. Therefore, it is critical to elucidate mechanisms by which ERα expression is regulated. We show that the tumor suppressor E3 ligase COP1 promotes the degradative polyubiquitination of the microtubule-associated protein HPIP. As such, COP1 negatively regulates estrogen-dependent AKT activation in breast cancer cells. However, COP1 also induces ERα expression and ERα-dependent gene transcription, at least through c-Jun degradation. COP1 and ERα levels are positively correlated in clinical cases of breast cancer. COP1 also supports the metabolic reprogramming by estrogens, including glycolysis. On the other hand, COP1 suppresses EMT in breast cancer cells. COP1 deficiency also contributes to Tamoxifen resistance, at least through protective autophagy. Therefore, COP1 acts as an oncogenic E3 ligase by promoting ERα signaling but also acts as a tumor suppressor candidate by preventing EMT, which reflects a dual role of COP1 in breast cancer.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34716429 DOI: 10.1038/s41388-021-02038-3
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867